CClinicalTrials.gg
RecruitingNCT06166784Updated Dec 12, 2023

Interference Screw Mectascrew-B Postmarket Study

An observational study in Anterior Cruciate Ligament Injuries Posterior Cruciate Ligament Tear, sponsored by Medacta International SA. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-12.

Sponsored by Medacta International SA · Observational

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 2 years 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
27
Ages
18 Years and older
Sex
All
01

Study summary

An observational prospective study with the aim to assess the clinical outcomes at 1year after surgery for a specific composite IS (Medacta Mectascrew B) in the reconstructive treatment of ruptured ACL or PCL by means of an autograft or allograft.

Read the detailed description

This is an observational prospective study with the aim toassess the clinical outcomes at 1year after surgery for a specific composite IS (Medacta Mectascrew B) at 12 months following ACL or PCL reconstruction.

Patients with an ACL or PCL tear scheduled for surgery at OCM Klnik GmbH hospital will be enrolled in the study, after the subscription of informed consent.

The injured ligament will be restored with an auto- or allograft that will be fixed with a composite IS (Mectascrew-B, Medacta International SA). Data concerning demography, preoperative clinical conditions, surgical details including device implanted, tendon harvesting procedure and complications occurred, postoperative clinical data (as per standard practice at 6 weeks, 6 and/or 12 months) will be prospectively collected, in order to assess the functional outcomes (IKDC objective and subjective) and the knee stability (ROM, Pivot Shift or Reverse Pivot Shift test, anterior or posterior drawer test) of the patients.

The treated knee will be also evaluated radiologically by std x-ray according to standard practice to assess swelling, tunnel widening, and resorption problems. The results of this exam will be correlated to the pre-operative findings and to the functional and clinical outcomes evaluated with the different forms

02

Conditions studied

  • Anterior Cruciate Ligament Injuries Posterior Cruciate Ligament Tear
03

In context

Anterior Cruciate Ligament Injuries

511 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 163 are open to participants now.

This study's planned enrollment of 27 is below the median of 92 across 127 observational studies indexed under Anterior Cruciate Ligament Injuries.

Browse Anterior Cruciate Ligament Injuries studies →

Lead sponsor

Medacta International SA is the lead sponsor of 46 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with an ACL or PCL rupture, and meeting the inclusion/ exclusion criteria

Inclusion criteria

  • Both genders
  • Patients older than 18 years
  • ACL or PCL damage requiring primary ACL or PCL reconstruction
  • Patient requiring ACL or PCL surgery with the use of Medacta MectaScrew B interference screw, according to Manufacturer IFU's, i.e. reconstructive therapy of ruptures to the anterior or posterior cruciate ligament by means of autologous grafts
  • Patients who are willing to participate in the study and have signed informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Patients with contraindications according to IFU's
  • Patients with malignant diseases (at the time of surgery)
  • Patients with proven or suspected infections (at the time of surgery)
  • Patients with functional deficits on the affected extremity (at the time of surgery)
  • Patients with known incompatibility or allergy to products materials (at the time of surgery)
  • Concomitant ligament injury (grade ≥ 3)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
27 participants (estimated)
Patient registry
No

Groups and cohorts

  • Mectascrew B

    Device: Mectascrew B

Interventions

  • DeviceMectascrew B

    reconstruction of ACL or PCL rupture

06

What researchers measure

Primary outcomes

  1. Functional outcomes evaluation

    Assessment throught IKCD score. a patient-completed tool, which contains sections on knee symptoms (7 items), function (2 items), and sports activities (2 items). Scores range from 0 points (lowest level of function or highest level of symptoms) to 100 points (highest level of function and lowest level of symptoms).

    Time frame: 12 months

Secondary outcomes

  1. Mobility outcomes evaluation

    Assessment throught Range Of Motion of operated knee calculated as degree

    Time frame: 6 weeks, 6 months, 12 months

  2. Knee stability evaluation of ACL intervention

    Pivot shift test. A positive test indicate an injury at ACL

    Time frame: 6 weeks, 6 months, 12 months

  3. ACL integrity assessment

    Anterior drawer test. An anterior translation more than 6 mm indicate a positive test with injuried ACL

    Time frame: 6 weeks, 6 months, 12 months

  4. Knee stability evaluation of PCL intervention

    Reverse Pivot Shift test. In the presence of a posterolateral injury with the knee flexed, the tibia follows gravity and drops into posterolateral subluxation (positive Reverse Pivot Shift Test).

    Time frame: 6 weeks, 6 months, 12 months

  5. PCL integrity assessment

    Posterior drawer test. The test is considered positive if there is a lack of end feel or excessive posterior translation

    Time frame: 6 weeks, 6 months, 12 months

  6. Interference screw integration

    Evaluation of ligament osteointegration, femoral/tibial tunnel widening, presence of fluid in the femoral/tibial tunnel by std x-ray

    Time frame: 6 weeks, 6 months, 12 months

  7. Incidence of adverse event

    collection of adverse event

    Time frame: 6 weeks, 6 months, 12 months

07

Study locations

1 of 1 sites recruiting
  • OCM Klinik GmbH
    Münich, 81369, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06166784
Lead sponsor
Medacta International SA
Responsible party
Sponsor
First posted
Dec 12, 2023
Start date
Oct 19, 2023
Primary completion
Nov 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Dec 12, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion